Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population
Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population
This study aims to evaluate the immunogenicity, safety and tolerability of co-administration
 of vaccinations for meningitis B (Bexsero®) and meningitis ACWY (Menveo®) in adults and
 children aged 10-45 years living with HIV. All participants will be vaccinated with both
 Menveo® and Bexsero® on days 0 and 30. Immunogenicity will be determined on venous blood
 sampled at days 0 and 60. Adverse effects will be recorded to evaluate safety.
Inclusion Criteria:

 -  Any 10-45-year old male or female patients with confirmed HIV infection where they (or
 someone with parental responsibility) can sign fully informed consent and are able to
 comply with study requirements.

 Exclusion Criteria:

 -  Pregnancy or breast feeding,

 -  History of MenACWY (Menveo® or Nimenrix®) and 4CMenB (Bexsero®) vaccination in the
 previous 2 years,

 -  Receipt of other non-live vaccines within 2 weeks and live vaccines within 4 weeks of
 first dose, planned receipt of vaccine within 2 weeks of study visits,

 -  Current active malignancy,

 -  Known latex allergy

 -  Known or suspected hypersensitivity to any components of the vaccines or history of
 severe allergic reaction after previous vaccination

 -  Bleeding disorder preventing IM vaccination,

 -  Any acute or chronic illness which according to the investigators judgement would
 prevent patients to receive the vaccines or participate in the study

 -  Participation in clinical trials concerning investigational medical product within 0
 days or before completion of the study

 -  Children in care